The clinical success of EGFR kinase inhibitors gefitinib and eriotinib in EGFR mutant non-small cell lung cancer (NSCLC) is limited by the eventual development of acquired drug resistance. We and others have identified two main mechanisms of drug resistance: acquired secondary mutations in EGFR (EGFR T790M) and activation of HGF/MET signaling (either by MET amplification or by autocrine/paracrine production of HGF). In both instances, the resistant cancers maintain dependence on EGFR signaling, highlighting the need to develop novel EGFR-targeted therapies and/or combination therapeutic approaches. Irreversible quinazoline-based EGFR kinase inhibitors, including HKI-272, PF00299804. and B1BW2992, are effective in some preclinical models against EGFR T790M, but clinically their efficacy has been limited by lack of potency and toxicity (skin rash and diarrhea) due to concurrent on-target inhibition of wild-type (WT) EGFR. Recentiy, we identified irreversible pyrimidine EGFR kinase inhibitors (WZ4002) that are selective for the mutant EGFR receptor and are significantiy more potent against EGFR T790M than existing irreversible quinazoline EGFR inhibitors. Furthermore, these agents, unlike quinazoline irreversible EGFR inhibitors, prevent the emergence of EGFR T790M as a resistance mechanism using in vitro models. Although this new class of EGFR inhibitors may be clinically more effective than currentiy available agents, resistance is nevertheless expected to also develop to all irreversible EGFR inhibitors. In fact, a mutation in the covalent binding site (C797S) of EGFR alone is sufficient to cause resistance to both WZ4002 and HKI-272. In this project we propose to develop additional agents that can effectively inhibit EGFR in the presence of the C797S and other drug resistance mutations.
The specific aims are 1.) Characterize EGFR small molecule kinase inhibitors against irreversible EGFR kinase inhibitor resistance mutations. 2.) Identify resistance mechanisms to irreversible pyrimidine EGFR inhibitors and 3.) Determine the impact of targeting drug resistance mechanisms on the efficacy of irreversible pyrimidine EGFR inhibitors and the emergence of drug resistance.

Public Health Relevance

EGFR kinase inhibitors are effective clinical therapies for 30,000 patients in the United States diagnosed annually with EGFR mutant NSCLC. However, acquired drug resistance ultimately develops on all patients. Identification of effective therapies to treat drug resistant cancers is of great clinical and public health importance. We will synthesize and validate novel EGFR kinase inhibitors that may serve as novel therapies for EGFR mutant NSCLC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA154303-02
Application #
8559665
Study Section
Special Emphasis Panel (ZCA1-GRB-P)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
2
Fiscal Year
2013
Total Cost
$236,605
Indirect Cost
$88,519
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Wang, J; Mikse, O; Liao, R G et al. (2015) Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene 34:2167-77
Berger, A H; Imielinski, M; Duke, F et al. (2014) Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene 33:4418-23
Nakayama, Sohei; Sng, Natasha; Carretero, Julian et al. (2014) ?-catenin contributes to lung tumor development induced by EGFR mutations. Cancer Res 74:5891-902
Chen, Zhao; Akbay, Esra; Mikse, Oliver et al. (2014) Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res 20:1204-11
Herter-Sprie, Grit S; Korideck, Houari; Christensen, Camilla L et al. (2014) Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models. Nat Commun 5:5870
Lovly, Christine M; McDonald, Nerina T; Chen, Heidi et al. (2014) Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 20:1027-34
Christensen, Camilla L; Kwiatkowski, Nicholas; Abraham, Brian J et al. (2014) Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 26:909-22
Canning, Peter; Tan, Li; Chu, Kiki et al. (2014) Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors. J Mol Biol 426:2457-70
Chen, Zhao; Fillmore, Christine M; Hammerman, Peter S et al. (2014) Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 14:535-46
Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90

Showing the most recent 10 out of 24 publications